Related Experiment Video
Updated: Mar 2, 2026

In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
Are symptomatic endpoints acceptable in venous thromboprophylactic studies?
1Department of Clinical Medicine, General Infirmary and University of Leeds, UK.
Abstract:
Chemoprophylaxis with subcutaneous low-molecular-weight heparin has been shown to reduce deep vein thrombosis detected by surrogate endpoints such as fibrinogen scanning and venography. However, there have been few trials which have assessed clinical endpoints attributed to fatal and non-fatal pulmonary embolism following surgery. As these clinical endpoints are rare, large-scale trials using vascular mortality, vascular morbidity and the incidence of haemorrhage as clinical endpoints need to be performed to assess the efficacy of chemical thromboprophylaxis. The benefit of using clinical endpoints against the risk of haemorrhage should also be evaluated.
More Related Videos
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Venous Thrombosis IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis I: Introduction
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

